Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer.

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011 Dec; 26(12):2827-33.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.